BioTime (BTX) was Initiated by Ladenburg Thalmann to “Buy”. Ladenburg Thalmann advised their investors in a research report released on Sep 23, 2016.
BioTime opened for trading at $3.43 and hit $3.6 on the upside on Thursday, eventually ending the session at $3.59, with a gain of 3.16% or 0.11 points. The heightened volatility saw the trading volume jump to 3,70,988 shares. Company has a market cap of $371 M.
In a different news, on Nov 11, 2015, Angus C. Russell (director) purchased 50,000 shares at $3.83 per share price. According to the SEC, on Nov 10, 2015, Stephen C Farrell (director) purchased 50,000 shares at $3.83 per share price. On Aug 26, 2015, Deborah J Andrews (director) purchased 2,000 shares at $2.82 per share price, according to the Form-4 filing with the securities and exchange commission.
BioTime Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines including tissue banking cellular therapy gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases such as neurological disorders cancer age related macular degeneration orthopedic disorders and age-related cardiovascular disease.